Targeting Angiogenesis Taming the Medusa of Ovarian Cancer

被引：13

作者：

Dhani, Neesha C. ^{[1
,2
]}

Oza, Amit M. ^{[1
,3
]}

机构：

[1] Univ Toronto, Dept Med, Toronto, ON, Canada

[2] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 700 Univ Ave,Suite 7-817, Toronto, ON M5G 1Z5, Canada

[3] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 700 Univ Ave,Suite 7-925, Toronto, ON M5G 1Z5, Canada

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期

关键词：

Angiogenesis; Ovarian cancer; Maintenance; Vascular endothelial growth factor (VEGF); Bevacizumab; PEGYLATED LIPOSOMAL DOXORUBICIN; RECURRENT EPITHELIAL OVARIAN; BEVACIZUMAB-CONTAINING THERAPY; RANDOMIZED PHASE-III; DOUBLE-BLIND; OPEN-LABEL; PRIMARY PERITONEAL; WEEKLY PACLITAXEL; TRIAL; CHEMOTHERAPY;

D O I：

10.1016/j.hoc.2018.07.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Epithelial ovarian cancer remains the most lethal gynecologic cancers with a 5-year survival rate of less than 50%. Cytotoxic combinations are associated with incremental toxicity, leading to interest in evaluating cytotoxic/biologic combinations with improved therapeutic ratios. Angiogenesis is critical to the normal physiology of the gynecologic tract and a novel drug target. Current data suggests antiangiogenics should be considered a critical component of epithelial ovarian cancer treatment. Given the serious adverse event of gastrointestinal perforation/fistula in advanced disease, priority should be given to front-line treatment. Active investigation continues in the development of novel combinations with other biologics.

引用

页码：1041 / +

页数：17

共 55 条

[1]

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2]

Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review [J].

Al-Abd, Ahmed M. ;

Alamoudi, Abdulmohsin J. ;

Abdel-Naim, Ashraf B. ;

Neamatallah, Thikryat A. ;

Ashour, Osama M. .

JOURNAL OF ADVANCED RESEARCH, 2017, 8 (06) :591-605

[3]

Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. [J].

Gourley, Charlie ;

McCavigan, Andrena ;

Perren, Timothy ;

Paul, James ;

Michie, Caroline Ogilvie ;

Churchman, Michael ;

Williams, Alistair ;

McCluggage, W. Glenn ;

Parmar, Mahesh ;

Kaplan, Richard S. ;

Hill, Laura A. ;

Haifpenny, Iris A. ;

O'Brien, Earnonn J. ;

Raji, Olaide ;

Deharo, Steve ;

Davison, Timothy ;

Johnston, Patrick ;

Keating, Katherine E. ;

Harkin, D. Paul ;

Kennedy, Richard D. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[4]

Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients [J].

Avril, Stefanie ;

Dincer, Yasemin ;

Malinowsky, Katharina ;

Wolff, Claudia ;

Guendisch, Sibylle ;

Hapfelmeier, Alexander ;

Boxberg, Melanie ;

Bronger, Holger ;

Becker, Karl-Friedrich ;

Schmalfeldt, Barbara .

ONCOTARGET, 2017, 8 (58) :97851-97861

[5]

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses [J].

Bais, Carlos ;

Mueller, Barbara ;

Brady, Mark F. ;

Mannel, Robert S. ;

Burger, Robert A. ;

Wei, Wei ;

Marien, Koen M. ;

Kockx, Mark M. ;

Husain, Amreen ;

Birrer, Michael J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)

[6]

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial [J].

Bamias, A. ;

Gibbs, E. ;

Lee, C. Khoon ;

Davies, L. ;

Dimopoulos, M. ;

Zagouri, F. ;

Veillard, A. -S. ;

Kosse, J. ;

Santaballa, A. ;

Mirza, M. R. ;

Tabaro, G. ;

Vergote, I. ;

Bloemendal, H. ;

Lykka, M. ;

Floquet, A. ;

Gebski, V. ;

Pujade-Lauraine, E. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1842-1848

[7]

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[8]

The Contribution of Angiogenesis to the Process of Metastasis [J].

Bielenberg, Diane R. ;

Zetter, Bruce R. .

CANCER JOURNAL, 2015, 21 (04) :267-273

[9]

Birrer M, 2013, J CLIN ONCOL S, V33, P5505

[10]

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

← 1 2 3 4 5 6 →